Biotech News

AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AngioDynamics (ANGO)AngioDynamics2026-11-06 23:00 ESTCompany update

LATHAM, N.Y. --(BUSINESS WIRE)--Nov. 6, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced

AngioDynamics

Vascular and Interventional Technology AngioDynamics develops medical technologies that restore blood flow, remove thrombus and treat selected tumors. Its portfolio is organized around higher-growth interventional platforms and a broader medical-device business. Mechanical Thrombectomy AlphaVac and AngioVac are mechanical aspiration...

Recent company news

ANGOAngioDynamics2026-11-06 23:00 EST

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

ANGOAngioDynamics2026-10-08 10:02 EST

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

Stock data

Close: 11.81 USD
Market cap: 453.68M USD
Exchange: NASDAQ
Sector: MedTech
Location: United States

AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Related news

AngioDynamics to Participate in Upcoming Investor Conferences

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AngioDynamics

Recent company news